Check out our most popular compounded medications! Get Started
Dimercaptosuccinic Acid 200 mg Slow Release Capsules is a specialized medication designed to treat a variety of conditions, primarily those related to heavy metal poisoning such as lead and mercury, as well as Wilson's disease, a rare genetic disorder that leads to excessive copper accumulation in the body. This medication functions as a chelating agent, effectively binding to heavy metals in the body and aiding in their removal.
This particular formulation is encapsulated within Methocel E4M, a controlled-release polymer. This innovative design allows for the gradual release of the active ingredient over an extended period of time. The slow release mechanism offers sustained therapeutic effects, reducing the need for frequent dosing and thereby improving patient compliance, particularly for medications that require a controlled and prolonged release profile.
By allowing for a more gradual release of the medication into the body, the slow release capsules help to minimize the risk of side effects and maintain more consistent levels of the medication in the body.
Dimercaptosuccinic Acid 200 mg Slow Release Capsules is a appropriate treatment option for a variety of disease states. However, it is crucial to follow the instructions provided by your healthcare provider when taking this medication. If you have any questions or concerns about this formulation, please do not hesitate to reach out to us at Bayview Pharmacy. We are committed to providing comprehensive information and support to ensure the best possible patient outcomes.
Dimercaptosuccinic Acid 200 mg Slow Release Capsules are formulated with Methocel E4M, a controlled-release polymer. This design allows for the gradual release of the active ingredient over an extended period, providing sustained therapeutic effects, reduced dosing frequency, and improved patient compliance for medications requiring a controlled and prolonged release profile.
These capsules may interact with other medications, supplements, or herbal products. It is crucial for patients to inform their healthcare provider of all medications, supplements, and herbal products they are currently taking before starting this medication. Interactions may occur with antacids, iron supplements, and other medications that contain metals. Therefore, patients should avoid taking these within 2 hours of taking Dimercaptosuccinic Acid 200 mg Slow Release Capsules.
Interactions may also occur with certain antibiotics, such as penicillins, cephalosporins, and tetracyclines. If patients are taking any of these medications, they should inform their healthcare provider before starting Dimercaptosuccinic Acid 200 mg Slow Release Capsules. Certain antifungal medications, such as ketoconazole and itraconazole, may also interact with these capsules. Again, patients should inform their healthcare provider if they are taking any of these medications.
Dimercaptosuccinic Acid 200 mg Slow Release Capsules may also interact with certain medications used to treat seizures, such as phenytoin and carbamazepine. Patients should inform their healthcare provider if they are taking any of these medications. Additionally, certain medications used to treat depression, such as tricyclic antidepressants and selective serotonin reuptake inhibitors, may interact with these capsules. Patients should inform their healthcare provider if they are taking any of these medications before starting Dimercaptosuccinic Acid 200 mg Slow Release Capsules.
If you have any questions about the interactions of Dimercaptosuccinic Acid 200 mg Slow Release Capsules with other medications, supplements, or herbal products, please consult with your healthcare provider.
Dimercaptosuccinic Acid 200 mg Slow Release Capsules are a specialized formulation designed to treat a range of conditions such as lead poisoning, Wilson's disease, and cystinuria. The active ingredient in these capsules is dimercaptosuccinic acid, a potent chelating agent that binds to heavy metals and other toxins in the body, facilitating their excretion through urine.
The unique feature of these capsules is their slow-release formulation, achieved through the use of Methocel E4M, a controlled-release polymer. This design ensures a gradual and sustained release of the medication over an extended period, providing a consistent therapeutic effect. This slow-release mechanism not only enhances the efficacy of the medication but also reduces the frequency of dosing, thereby improving patient compliance, particularly for medications requiring a controlled and prolonged release profile.
When using Dimercaptosuccinic Acid 200 mg Slow Release Capsules, it is crucial to adhere to the prescribed dosage and schedule. The capsules should be consumed with food and ample water to ensure optimal absorption. Additionally, maintaining high fluid intake throughout the day is recommended to aid in the efficient flushing out of toxins from the body.
Patients should be cognizant of potential side effects such as nausea, vomiting, diarrhea, and abdominal pain. In the event of experiencing any of these side effects, immediate medical attention should be sought. It is always advisable to discuss any concerns or queries about the medication with a healthcare professional.
Dimercaptosuccinic Acid 200 mg Slow Release Capsules represent a significant advancement in the treatment of conditions involving heavy metal and toxin accumulation in the body. Their slow-release formulation ensures a steady therapeutic effect, making them a valuable tool in the management of these conditions.
Dimercaptosuccinic Acid 200 mg Slow Release Capsules, formulated with Methocel E4M, a type of controlled-release polymer, are designed to gradually release the encapsulated medication over an extended period of time. This slow-release mechanism offers sustained therapeutic effects, reduces dosing frequency, and improves patient compliance for medications requiring a controlled and prolonged release profile. These capsules can be used to treat a variety of conditions including heavy metal poisoning from substances such as copper, iron, and zinc.
Furthermore, Dimercaptosuccinic Acid 200 mg Slow Release Capsules can be used to treat certain types of kidney stones, specifically cystine stones. They are also beneficial in treating certain types of anemia, such as sideroblastic anemia, and certain types of liver disease, including primary biliary cirrhosis. These capsules can also be used to treat certain types of kidney disease, such as Fanconi syndrome, and certain types of skin disorders, such as erythema nodosum.
If you have any questions about the use of Dimercaptosuccinic Acid 200 mg Slow Release Capsules for any of these conditions, please do not hesitate to reach out for more information. It is important to note that the effectiveness of this medication may vary depending on the individual patient's condition and response to treatment.
Dimercaptosuccinic Acid 200 mg Slow Release Capsules is a medication that is encapsulated in a controlled-release polymer, Methocel E4M. This formulation is designed to gradually release the active ingredient over an extended period of time.
Methocel E4M is a type of controlled-release polymer. It is used in the formulation to ensure that the medication is released gradually over a prolonged period, offering sustained therapeutic effects.
A slow release formulation offers several benefits. It provides sustained therapeutic effects, reduces the frequency of dosing, and improves patient compliance, especially for medications that require a controlled and prolonged release profile.
The frequency of dosing will depend on your doctor's prescription. However, due to the slow release formulation, the frequency of dosing is typically reduced compared to regular medications.
'Improved patient compliance' means that patients are more likely to take the medication as prescribed. This is because the slow release formulation reduces the frequency of dosing, making it more convenient for patients.
No, the slow release formulation does not affect the effectiveness of the medication. In fact, it enhances the therapeutic effects by ensuring a steady release of the medication over an extended period of time.
No, the capsule should not be opened or crushed. Doing so can disrupt the controlled-release mechanism and may lead to a sudden release of the medication, which can have adverse effects.
If you miss a dose, take it as soon as you remember. However, if it is close to the time for your next dose, skip the missed dose and go back to your regular dosing schedule. Do not take two doses at the same time.
Generally, this medication can be taken with or without food. However, it's always best to follow your doctor's specific instructions regarding food and medication intake.
In case of an overdose, seek immediate medical attention. Symptoms of an overdose may include nausea, vomiting, stomach pain, and others. Always follow your doctor's prescribed dosage to avoid an overdose.
This formulation is compounded by Bayview Pharmacy on a prescriber's order for an individual patient. It is not an FDA-approved drug product, and the FDA has not evaluated it for safety, effectiveness, or manufacturing quality.
The conditions listed on this page are indications prescribers have ordered this preparation for. They are not FDA-approved indications, and listing them is not a statement that this preparation is effective for them.
A valid prescription is required. Availability depends on Bayview's licensure in your state. This page is general information, not medical advice — discuss your situation with a licensed healthcare provider.
Search by NCPDP 4106882, or by name and ZIP: Bayview Pharmacy, Warwick, RI 02886. Select it as the destination pharmacy and save it as a favorite. Click any value to copy it.
Compounded preparations have no NDC, so this formula will not appear in your EHR's drug search. Use your system's compound, non-formulary, or free-text prescription entry and name the preparation exactly as written in step 3. If your EHR forces you to pick a listed drug, pick the closest entry for the active ingredient and put the full formula in the prescription body (the Sig or directions field), not in Notes to Pharmacy.
Compounded preparations have no NDC and will not appear in your drug search. For EPCS to validate, select a drug entry your EHR recognizes as controlled, usually the bulk powder entry for the active ingredient (for example Ketamine (bulk) powder, not a branded product), then put the full formula from step 3 in the prescription body. A free-text entry that does not validate as controlled will be rejected by your EPCS module.
Quantity and directions are starting points for this dose form, not treatment recommendations. Dosing remains the prescriber's responsibility.
Transmit from your EHR. For this non-controlled preparation we also accept fax to (401) 284-4506 and phoned orders at (401) 284-4505. Order forms are on the formulation pages and in the prescriber portal.
Transmit with two-factor authentication through your EPCS-enabled EHR. No order form is offered for this preparation; e-prescribing guides for our controlled preparations are on the formulation pages.
Licensed to dispense in RI, MA, CT, NY, NJ, NH, FL, and ME. Compounded preparations are not FDA-approved. A valid prescription is required. Full guide, including steps by EHR: How to e-prescribe to Bayview. Questions about this formula: call (401) 284-4505.
Take 1 capsule by mouth
